SDF-1 inhibition targets the bone marrow niche for cancer therapy. - Wikidata - awgldk - TriplyDB

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

http://www.wikidata.org/entity/Q34324830

about

Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate.The notorious R.N.A. in the spotlight - drug or target for the treatment of disease The importance of the genomic landscape in Waldenström's Macroglobulinemia for targeted therapeutical interventions.Pathogenesis beyond the cancer clone(s) in multiple myeloma.SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction.Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast Mist1 Expressing Gastric Stem Cells Maintain the Normal and Neoplastic Gastric Epithelium and Are Supported by a Perivascular Stem Cell Niche.Navigating the bone marrow niche: translational insights and cancer-driven dysfunction.CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma.CXCL12/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks.Adipocyte-Lineage Cells Support Growth and Dissemination of Multiple Myeloma in Bone.Adipose, Bone, and Myeloma: Contributions from the Microenvironment.Microenvironment drug resistance in multiple myeloma: emerging new players.Targeting the Bone Marrow Microenvironment.MGUS to myeloma: a mysterious gammopathy of underexplored significance.Mechanisms of Resistance in Multiple Myeloma.Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib-dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study.Newly established myeloma-derived stromal cell line MSP-1 supports multiple myeloma proliferation, migration, and adhesion and induces drug resistance more than normal-derived stroma.Promising therapies in multiple myeloma.Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition.Dynamic cellular phynotyping defines specific mobilization mechanisms of human hematopoietic stem and progenitor cells induced by SDF1α versus synthetic agents.CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.The bone-marrow niche in MDS and MGUS: implications for AML and MM.Aptamer Therapeutics in Cancer: Current and Future.The bone marrow metastasis niche in retinoblastoma.Role of Tumor-Derived Chemokines in Osteolytic Bone Metastasis.The NF-κB Activating Pathways in Multiple Myeloma.

P2860

Q26744596-65629239-6584-4245-89F0-F1D59FB81F53 Q33591618-4F6F6BE7-7F99-4F93-8989-25B8A23801C2 Q33695185-1DC95B0B-A2F8-4961-80F3-34E1101BA36A Q33739733-F89111DE-65C1-4E4F-9F88-922B9A715584 Q33798887-C9C4AB04-05E8-414A-80BF-2D9D0DC603B8 Q35607266-39041F63-BDE2-400F-ADD9-347E6B2BEA3A Q35732102-47330333-CC60-4E8D-A706-BAE8DEEE9D0E Q36086488-6F1BEB6E-4A67-494C-8B3E-6B7E4D07A13D Q36386294-E6CA7000-3128-45B8-8E8F-0879A5D4F062 Q37101382-BEB3A38C-87F1-4D60-9143-99B310DE7D80 Q37127055-0E3C814C-C198-4558-A3AA-22D1FCA7D733 Q37694678-4B127B83-0CA9-4181-A027-5BD78870C769 Q38472331-2EB0AEDC-CEE3-4CB7-AD0E-3F6C8DD5D35F Q38736038-7334D97B-81B0-40B3-9645-52E5C0180F96 Q38876521-DA4D089E-6F47-4F3B-A481-649FD184024C Q38913083-60785FBF-8FD8-4EFF-B66A-5CD03D0C4758 Q38970585-C03AD78C-BBA4-4E48-A155-C047177EC528 Q38979865-33F05327-2145-43D3-AF7E-EF9433E777E4 Q39185604-01A4FC79-CB5C-447E-9078-771933E1FBD9 Q42046604-F2CB4200-7C5E-4DA7-9F1C-12B5373317F7 Q42399819-7F5B7C2A-42B8-4C4D-A20E-8AA29A17857F Q42581682-30DCE10A-C7D9-422D-B54E-6CD2CB05ECE5 Q47093658-CDBCC7AD-67E9-43EB-B139-6FFFD3FC6C4D Q48138880-D1C42478-9E4F-442C-BC14-65A091712CFA Q48188365-A997DC0A-0876-4173-99C3-402FE6E38FAB Q50114615-5744308F-3126-4CD5-BAEF-906E1FA906A6 Q52347485-B5C558EE-949A-4E76-9959-F3C0AEED77BF Q53471802-CA4C1108-CE10-4913-B6FC-8C04479F2A0A Q55477815-C108B343-FE22-478F-A469-5C7A7A7DD9E5 Q55657825-13709C0C-91DA-4AAC-8903-D883D61EC2A7

P2860

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

http://www.wikidata.org/entity/Q34324830

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@ast

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@en

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@nl

type

label

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@ast

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@en

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@nl

prefLabel

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@ast

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@en

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@nl

P1433

Q34324830-7C282C8A-20C1-496D-A42D-5E38B032601B

P1476

Q34324830-725ED36F-C318-4415-81EE-6EC2C913EDCF

P2093

Q34324830-11A3E275-6763-43A3-A768-4906F3C1E6FB

Q34324830-5F729348-163E-4717-821B-7B7137323F4F

Q34324830-69D630E1-86A4-4A95-A44D-747E16ABA881

Q34324830-6B04CA06-6BA8-4566-B019-CD2676CF2576

Q34324830-6FA5DD54-8DBA-45D9-96A8-BF01B9A8CD0C

Q34324830-8C3F732B-6699-4144-93A5-DCCC17D3F8ED

Q34324830-A967ABE7-7BB6-4A5D-B344-94806C655969

Q34324830-AB26B139-5F92-42EF-9554-D85DD6C1F470

Q34324830-B2445BFF-C135-4996-95C9-D410B533C959

Q34324830-B8BAFC26-E115-40D8-AC9C-95625A967104

P2860

Q34324830-047676E4-E55E-4AA2-9B1A-C2CC2C95C625

Q34324830-09A684EB-321E-40EB-B05C-EF9F087A28E9

Q34324830-0BBA63D7-294D-485B-B8D4-21E85F3A7119

Q34324830-1DDE185A-268E-4DE4-AC7C-EB7A60288E5C

Q34324830-2A03C2C7-3A64-4397-BDA6-9D5BE6DEA4E9

Q34324830-3155193B-4978-4D9E-969D-D42CE7EFDD30

Q34324830-3FC7B65D-971B-46A6-A385-2A1BCF9841B6

Q34324830-435B5FDB-117E-4C27-A5C8-B5B2588B0D41

Q34324830-4F8A68ED-6AB2-48D8-8E22-3E7FE02F42F4

Q34324830-656B3B70-EF1D-4A0E-9DBC-D6D1AEF105BF

P304

Q34324830-70C0D5E5-172A-4CBB-9BC0-87CEA6DD19B8

P31

Q34324830-A1231AEB-2B1A-4DF7-90AE-AA105D95E564

P356

Q34324830-8296833D-7D65-4E32-A723-1B31AADC1ABC

P433

Q34324830-F57035CC-45FC-4E42-89D8-53177767194C

P478

Q34324830-4996F26E-7E19-480B-930B-858920F99245

P50

Q34324830-00783713-36E4-4FD8-9CC7-3C1EA4118A6D

Q34324830-07AEBB40-20DC-47F7-A549-1B0AFD365143

Q34324830-2CB845AC-02D6-41F9-9DF4-CD4A28769F0E

Q34324830-3CC7B7EA-AC03-4130-868E-43BFAD7EA94D

Q34324830-BE98EB3C-B61D-4B7B-B0BD-78885F0FC802

Q34324830-CC8476AB-B1B5-43DD-8202-1163E1E3EE71

Q34324830-E0529962-B340-44DB-AE14-28F2584785DF

P577

Q34324830-E14B1383-35EB-4F00-BE7F-41F351B80FD3

P5875

Q34324830-9C91019F-0E8B-47AF-8AED-71AFBB8C1281

P698

Q34324830-0C4A6494-02AB-41C7-89A8-6C998882A9F6

P921

Q34324830-9B3CD993-D3AB-49B2-9B64-7C3FFE1ED122

P932

Q34324830-1C9E5224-ACA4-4038-8062-725116936499

P356

J.CELREP.2014.08.042

P1433

P1476

SDF-1 inhibition targets the bone marrow niche for cancer therapy.

@en

P2093

Anna Kruschinski

http://www.w3.org/2001/XMLSchema#string

Christian Maasch

http://www.w3.org/2001/XMLSchema#string

Dirk Eulberg

http://www.w3.org/2001/XMLSchema#string

Dirk Zboralski

http://www.w3.org/2001/XMLSchema#string

Irene M Ghobrial

http://www.w3.org/2001/XMLSchema#string

Klaus Buchner

http://www.w3.org/2001/XMLSchema#string

Marco Ungari

http://www.w3.org/2001/XMLSchema#string

Michele Moschetta

http://www.w3.org/2001/XMLSchema#string

Silvia Lonardi

http://www.w3.org/2001/XMLSchema#string

Stefan Vonhoff

http://www.w3.org/2001/XMLSchema#string

P2860

Mfold web server for nucleic acid folding and hybridization prediction

A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)

CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature

Circadian control of the immune system

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

The stem-cell niche as an entity of action

CXCR4 regulates growth of both primary and metastatic breast cancer

The distribution of secondary growths in cancer of the breast. 1889

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

Tumor metastasis: molecular insights and evolving paradigms

P304

118-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELREP.2014.08.042

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Michaela R. Reagan

Fabio Facchetti

P577

2014-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266082121

http://www.w3.org/2001/XMLSchema#string

P698

25263552

http://www.w3.org/2001/XMLSchema#string

P921

P932

4194173

http://www.w3.org/2001/XMLSchema#string